临床试验/NCT07824843

NCT07824843尚未招募1 期

A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GMDTC in Participants With Solid Tumors Who Have Cisplatin-Induced Renal Insufficiency

Guangdong Jianersheng Pharmaceutical Technology Co., Ltd.1 个研究点分布在 1 个国家目标入组 60 人开始时间: 2026年10月1日最近更新: 2026年9月17日

适应症

干预措施

试验速览

阶段: 1 期
状态: 尚未招募
发起方
入组人数: 60
试验地点: 1
主要终点: Adverse events

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This trial is a multicenter, combined hydration, multiple-dose, dose-escalation phase Ib clinical study, designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of the injection product GMDTC in participants with solid tumors and cisplatin-induced mild renal impairment.

详细描述

The primary objective of this study is to evaluate the safety and tolerability of GMDTC in a single-dose, dose-escalation study in participants with mild renal impairment who are scheduled to receive cisplatin-based chemotherapy for solid tumors, and to determine the recommended phase II dose (RP2D) for this drug. The secondary objective is to evaluate the pharmacokinetic (PK) characteristics, pharmacodynamic (PD) characteristics, and renal function improvement after single-dose multiple administration of GMDTC following cisplatin chemotherapy in this group of participants.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•The subject is able to understand and voluntarily sign a written Informed Consent Form (ICF), agreeing to comply with the study protocol.
•When signing the ICF, the participant must be at least 18 years of age, regardless of gender.
•The expected survival period of the subjects is ≥ 6 months.
•The subjects have an ECOG performance status score of 0 or
•Malignant solid tumors (excluding renal cell carcinoma) diagnosed by histological or cytological examination must simultaneously meet the following criteria:
•Participants who have previously received cisplatin-based chemotherapy and developed mild cisplatin-induced renal insufficiency, and who are still scheduled to undergo cisplatin-based chemotherapy; Mild renal insufficiency is defined as: during the screening phase, estimated glomerular filtration rate (eGFR) ≥ 60 and < 90 mL/min/1.73 m² (calculated using the CKD-EPI formula).
•Within 7 days prior to the first administration, participants shall be assessed for adequate bone marrow function, as well as normal cardiac, pulmonary, hepatic, and coagulation function, based on the following laboratory tests (transfusion or administration of other growth factor-based supportive therapy is prohibited within 14 days prior to the first dose of the investigational product):
•Bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L, platelet count ≥ 100 × 10^9/L, and hemoglobin ≥ 90 g/L; Liver function: Total bilirubin (TBIL) ≤ 1.5 × ULN, or total bilirubin (TBIL) ≤ 3 × ULN (in cases of Gilbert syndrome); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.0 × ULN (≤ 5 × ULN if hepatic metastases are present); Serum albumin (ALB) ≥ 30 g/L; Coagulation function (in patients not receiving anticoagulant therapy): Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN; Prothrombin time (PT) or International Normalized Ratio (INR) ≤ 1.5 × ULN. Patients receiving long-term anticoagulant therapy may participate in the study provided they have been on a stable anticoagulant dose for at least one month prior to the first administration of the investigational product. Unless the anticoagulant is a factor Xa inhibitor, a stable dose must be maintained for at least one week.
•Women of childbearing potential must agree to take reliable contraceptive measures or abstain from sexual activity from the moment they sign the informed consent form until 6 months after the last administration of the investigational drug. Women of childbearing age must have a negative serum pregnancy test within 7 days before the first dose.
•Male participants must agree to take reliable contraceptive measures or abstain from sexual activity from the moment they signed the informed consent form until six months after the last administration of the investigational drug. Additionally, male participants must agree not to donate sperm during this period.

排除标准

•Those who have participated in any other clinical trials within 4 weeks before the first administration of the investigational drug or within 5 half-lives (whichever is shorter);
•Those who are known or suspected to be allergic to any active ingredient or excipient of this product, or who have a specific history of allergic reactions as determined by the investigator to be unsuitable for treatment with the investigational drug;
•Those who are known or suspected to be allergic to any active ingredient or excipient of cisplatin or any other platinum-based drugs;
•The researchers identified those participants who would require a dose adjustment of cisplatin upon their first administration after being included in the study.
•Previous administration and toxicity recovery status:
•Before the first administration of the investigational drug, all adverse events (AEs) experienced by the participants during previous anti-tumor administration had not returned to baseline levels or were ≤ grade 1 (based on NCI CTCAE V6.0). Participants with the following conditions are allowed to be included: alopecia (any grade), participants with renal insufficiency (estimated glomerular filtration rate (eGFR) ≥ 45 ml/min/1.73 m2); participants with other AEs (≤ grade 2), and their inclusion is determined by the investigator;
•Those who have taken any drugs or health supplements (such as SGLT2 inhibitors like dapagliflozin, canagliflozin, empagliflozin, englestat, canagliflozin, hexagliflozin, igliflozin, rugliflozin, togliflozin, and natural compounds like aesculin; GLUT2 inhibitors such as cytochalasin B, aesculin, Huoxiang Zhengqi San, luteolin and isofraxidin) that may have interactions with the investigational drug within 4 weeks before the first administration of the investigational drug or 5 half-lives (whichever is longer) are excluded from the study.
•Those who have taken any drugs or health supplements (such as colchicine, probenecid, antihistamines, phenothiazine drugs, aminoglycoside antibiotics, amphotericin B, cephalothin, chloramphenicol or its furan benzenic acid or furoxan sodium, penicillamine or other chelating agents) that may have interactions with cisplatin within 4 weeks before the last cisplatin administration or 5 half-lives (whichever is longer) will be excluded from the screening.
•Participants with a history of peripheral neuropathy caused by cisplatin.
•Participants with chickenpox or shingles, except those who have been cured in the past.
•Participants with gout and hyperuricemia.
•Participants with a history of type 1 diabetes or type 2 diabetes accompanied by kidney disease.
•Patients with severe hepatobiliary disorders, decompensated liver cirrhosis (Child-Pugh class B or C), portal hypertension-related complications (ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy), or any form of cholestatic liver disease.
•Patients who have previously undergone liver transplantation or are scheduled for liver transplantation.
•Participants with meningeal metastasis.
•Uncontrolled CNS metastases are excluded.However, Participants with symptomatic CNS metastases may be eligible if the metastases are limited to the supratentorial and/or cerebellar region (i.e., without metastasis to the midbrain, pons, medulla oblongata, or spinal cord), local treatment has been received, neurological symptoms have been stable for at least 2 weeks before the first dose, and the participant does not require hormone therapy or is receiving ≤ 10 mg/day prednisone (or equivalent).
•Within 5 years prior to the first administration of the investigational drug, the subject had other malignant tumors (excluding the solid tumor diseases treated with cisplatin as part of this study, and excluding skin basal cell carcinoma, superficial bladder cancer, in situ cervical cancer, etc., which were considered eligible for inclusion by the investigators and had not recurred within the previous 5 years).
•There is a history of previous administration of allogeneic organ transplantation or allogeneic peripheral blood stem cell (PBSC)/immune cell/marrow transplantation.
•The subject had undergone major surgical procedures within 4 weeks prior to the first administration of the investigational drug, or had not yet fully recovered from any previous invasive procedures.
•Clinically significant cardiovascular diseases include:
•Within 6 months prior to the first administration of the investigational drug, there was a myocardial infarction, unstable angina pectoris, viral myocarditis or other uncontrolled heart disease;
•Left ventricular ejection fraction (LVEF) < 50%, congestive heart failure with NYHA cardiac function classification of II-IV;
•Symptomatic orthostatic hypotension occurred within 6 months prior to the first administration of the investigational drug;
•Uncontrolled hypertension [after standard medication, systolic blood pressure (SBP) ≥ 160 mmHg and/or diastolic blood pressure (DBP) ≥ 100 mmHg or a history of hypertension crisis or hypertensive encephalopathy];
•QTc > 470 ms (female), QTc > 450 ms (male), or a known family history of long QT syndrome;
•History of cardiac surgery such as angioplasty or coronary artery bypass grafting within 6 months prior to the first administration of the investigational drug;
•Uncontrolled seizures despite appropriate medical treatment.
•Within 6 months prior to the first administration of the investigational drug, the subject had experienced cerebral infarction, cerebral hemorrhage or transient ischemic attack.
•Those with interstitial pneumonia or interstitial lung disease, or those who have a history of interstitial pneumonia or interstitial lung disease that affects self-care daily activities or is accompanied by life-threatening respiratory disorders; or those with a history of pulmonary fibrosis, persistent pneumonia, pneumonia caused by drugs or radiotherapy, congenital pneumonia, or any evidence of active pneumonia found on chest CT scan. Or those with severe pulmonary diseases, including but not limited to pulmonary embolism that occurred within 3 months before the first administration, severe asthma, chronic obstructive pulmonary disease (COPD), restrictive lung disease, or active pneumonia, or those whose pulmonary function test indicates severe impairment of lung function.
•Those with a history of acute or chronic renal disease due to causes other than cisplatin treatment, or with a history of kidney transplantation, or currently undergoing renal replacement therapy (such as dialysis), or having persistent hematuria for unknown reasons, etc.
•Clinically uncontrolled serous cavity effusion (including pleural, pericardial, or peritoneal effusion), as determined by the investigator, is defined as requiring a drainage tube or drainage more than once weekly, and shall be excluded.
•Participants who have received a live attenuated vaccine within 4 weeks prior to the first administration of the investigational drug, or who are expected to require such vaccination during the study, are excluded.
•According to the researchers' assessment, there is a history or current condition of autoimmune diseases (such as myasthenia gravis or periodic hypokalemia), severe or uncontrolled systemic diseases, active bleeding disorders or active infections;
•Participants with active hepatitis B (HBsAg positive and HBV-DNA ≥ 1000 copies/mL or 500 IU/mL or the lower limit of the center's detection), or active hepatitis C (HCV antibody positive and HCV-RNA above the upper limit of the normal value), or positive screening result for human immunodeficiency virus (HIV) antibody, or active syphilis infection, or active tuberculosis infection will be excluded during the screening process.
•Female participants who are pregnant or breastfeeding;
•Those who have a clear history of neurological or mental disorders, such as dementia, and have poor compliance.
•Other serious diseases, or any other circumstances that the researcher deems may increase the risks for the participants or interfere with the test results, and any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.

研究组 & 干预措施

GMDTC Group

Experimental

All participants receive high-dose cisplatin chemotherapy (75mg/m2) on day 1 , followed by GMDTC administration via intravenous drip. The dosage is 0.5 grams per vial, in 1000 mg, 2000 mg, and 3000 mg once a day. The medication is administered once daily on Days 1-5 of each cycle. Among them, GMDTC starts to be administered 2 hours ± 15 minutes after the cisplatin administration on day 1.

GMDTC is reconstituted and diluted with 0.9% sodium chloride injection before administration. The total volume of the liquid for the trial drug GMDTC infusion each day is 1000 ml.

干预措施: GMDTC 1 mg/ml (Drug)

GMDTC Group

Experimental

GMDTC is reconstituted and diluted with 0.9% sodium chloride injection before administration. The total volume of the liquid for the trial drug GMDTC infusion each day is 1000 ml.

干预措施: GMDTC 2mg/ml (Drug)

GMDTC Group

Experimental

GMDTC is reconstituted and diluted with 0.9% sodium chloride injection before administration. The total volume of the liquid for the trial drug GMDTC infusion each day is 1000 ml.

干预措施: GMDTC 3mg/ml (Drug)

结局指标

主要结局

Adverse events

时间窗: Up to 90 days

Adverse events will be evaluated according to the NCI Common Terminology Criteria for Adverse Events (CTCAE, V6.0), which includes spontaneously reported adverse events as well as clinically significant changes in vital signs, physical examination, laboratory tests, electrocardiogram, and other examinations conducted during the trial.

DLT

时间窗: 21 days after the participant completes the first dose in the dose-escalation phase.

DLT is defined as any TEAE (including those definitely related, likely related, and possibly related) to GMDTC that occurs during the DLT observation period (the severity of adverse events \[Adverse events, AE\] is evaluated according to NCI CTCAE V6.0) or any clinically significant abnormal laboratory test results.

RP2D

时间窗: From first participant enrollment to the completion of the entire study, approximately 1 year.

RP2D is defined as the Recommended Phase 2 dose.

次要结局

Pharmacokinetic parameters,Tmax(Cycle 1 Days 1-5)
Pharmacokinetic parameters, Cmax(Cycle 1 Days 1-5)
Pharmacokinetic parameters, λz(Cycle 1 Days 1-5)
Pharmacokinetic parameters, t1/2(Cycle 1 Days 1-5)
Pharmacodynamic parameters, urine platinum(Baseline (the day before first dose) and Day1 to Day5 of each cycle.)
Pharmacodynamic parameters, amount of platinum excreted in urine over 24 hours(Baseline (the day before first dose) and Day1 to Day5 of each cycle.)
Renal function indicators： creatinine clearance(Baseline(Within 3 days before Cycle 1 treatment),D6 after the last cisplatin treatment prior to enrollment,D15 after the last cisplatin treatment prior to enrollment,Day 6 of each Cycle ,Day 15 of each Cycle,Day 20 of each Cycle)
Pharmacodynamic parameters,Urine platinum excretion rate(Baseline (the day before first dose) and Day1 to Day5 of each cycle.)
Renal function indicators：serum creatinine(Baseline(Within 3 days before Cycle 1 treatment),D6 after the last cisplatin treatment prior to enrollment,D15 after the last cisplatin treatment prior to enrollment,Day 6 of each Cycle ,Day 15 of each Cycle,Day 20 of each Cycle)
Renal function indicators：urea nitrogen/urea,(Baseline(Within 3 days before Cycle 1 treatment),D6 after the last cisplatin treatment prior to enrollment,D15 after the last cisplatin treatment prior to enrollment,Day 6 of each Cycle ,Day 15 of each Cycle,Day 20 of each Cycle)
Renal function indicators：estimated glomerular filtration rate (eGFR)(Baseline(Within 3 days before Cycle 1 treatment),D6 after the last cisplatin treatment prior to enrollment,D15 after the last cisplatin treatment prior to enrollment,Day 6 of each Cycle ,Day 15 of each Cycle,Day 20 of each Cycle)
Renal function indicators：cystatin C(Baseline(Within 3 days before Cycle 1 treatment),D6 after the last cisplatin treatment prior to enrollment,D15 after the last cisplatin treatment prior to enrollment,Day 6 of each Cycle ,Day 15 of each Cycle,Day 20 of each Cycle)
Renal function indicators：24-hour urine protein quantification(Baseline (the day before first dose) ,Day 1of each Cycle)

研究者

发起方

Guangdong Jianersheng Pharmaceutical Technology Co., Ltd.

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

尚未招募

1 期

Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer SubjectsBreast Cancer

NCT07697443Chia Tai Tianqing Pharmaceutical Group Co., Ltd.306

招募中

1 期

A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid TumorsProstate CancerGRPR-positive Solid TumorsBreast CancerColorectal Cancer

NCT07661641Alpha-9 Oncology USA Inc.115

招募中

1 期

A Clinical Trial of P134 Cells in Recurrent Glioblastoma

NCT07318818Tasly Pharmaceutical Group Co., Ltd26

尚未招募

1 期

A Study of SYS6051 in Subjects With Advanced Solid TumorsAdvanced Solid Tumors

NCT07591285CSPC Megalith Biopharmaceutical Co.,Ltd.114

招募中

1 期

A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases

NCT07614191Vivacta Biotechnology (Shanghai) Co., Ltd.22